Pharmaceutical company Hikma Pharmaceuticals plc (LON:HIK) revealed on Thursday that it has received US Food and Drug Administration (FDA) approval for and launched its generic version of GlaxoSmithKline's Advair Diskus (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg, in the United States.
The fixed dose combination product contains an inhaled corticosteroid (ICS) and a long-acting beta-adrenergic agonist (LABA) and is indicated for the twice-daily treatment of asthma in patients aged 4 years and older.
Hikma worked with Vectura Group (LON:VEC), a UK-based provider of inhaler drug delivery solutions, to develop the proprietary dry powder inhaler and formulation technology.
For the 12 months ending September 2020, US sales of Fluticasone Propionate and Salmeterol Inhalation Powder USP, 100mcg/50mcg and 250mcg/50mcg, were approximately USD2bn, according to IQVIA,
Campanelli Named to Slayback Board of Directors
Dr. Reddy's Laboratories Launches Lansoprazole DR Orally Disintegrating Tablets in the US Market
Dr. Reddy's Laboratories Launches Capecitabine Tablets, USP in the US Market
Dr Reddy's Laboratories launches Fluphenazine Hydrochloride Tablets, USP in US antipsychotic market
Akorn Operating's Loteprednol Etabonate Ophthalmic Gel, 0.5% receives US FDA approval
Dr. Reddy's Laboratories Launches Vigabatrin Tablets, USP in the US Market
Dr. Reddy's Laboratories unveils Vigabatrin Tablets, USP in the US Market
Sandoz introduces generic Icatibant injection pre-filled syringe in US
Xspray Pharma commences study with modified formulation of HyNap-Dasa
CONTINUUS Pharmaceuticals receives USD69.3m US government contract
Sputnik V Meets Primary Endpoint of Safety in India Phase 2 Clinical Trial
Amneal Launches Generic Abiraterone Acetate Tablets, USP, 500 mg, Following ANDA Approval by FDA